Exercise On Bone Metabolism Markers In Chronic Kidney Disease (intervention)
Aerobic Versus Resistance Exercise On Bone Metabolism Markers In Chronic Kidney Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Badr University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Non-smokers,
- no alcohol consumption
- no intake of hormone replacement therapy
- mass index ranged from 20-24 kg/m2.
Exclusion Criteria:
- diabetes disorders
- hypertension disorders
- cardiac disorders
- musculoskeletal disorders
- endocrine disorders
- intake of medications that may affect bone metabolism.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group (A)
Participants received resisted exercise training on some resistance machines
|
resistance exercises on some resistance machines, 3 sessions of exercise training /week
|
|
Experimental: group (B)
Participants received treadmill exercise training
|
treadmill aerobic exercise (intensity equal 60-80 % of each individual maximum heart rate)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum osteoprotegerin (OPG)
Time Frame: at baseline and after six month
|
An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C
|
at baseline and after six month
|
|
receptor activator of nuclear factor kappa B ligand
Time Frame: at baseline and after six month
|
An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C
|
at baseline and after six month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone mineral density (BMD)
Time Frame: at baseline and after six month
|
BMD of lumbar spine (L1-L4), proximal femur and distal radius was measured with dual-energy X-ray absorptiometry (DEXA).
|
at baseline and after six month
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency, Chronic
Other Study ID Numbers
Other Study ID Numbers
- SU.REC.2025(45H)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.